JY207b

JY207b: sourced facts only. name: "Meanwhile, JY207b could still preferentially bind to CD47/PD-L1 double positive tumor cells, thus reducing the possibility of on-target toxicities." [DOI:10.1158/1538-7445.am2024-3126]; target: "Meanwhile, JY207b could still preferentially bind to CD47/PD-L1 double positive tumor cells, thus reducing the possibility of on-target toxicities." [DOI:10.1158/1538-7445.am2024-3126]; target: "Meanwhile, JY207b could still preferentially bind to CD47/PD-L1 double positive tumor cells, thus reducing the possibility of on-target toxicities." [DOI:10.1158/1538-7445.am2024-3126]; developer: "1Shenzhen Enduring Biotech, Ltd., Shenzhen, China." [DOI:10.1158/1538-7445.am2024-3126]; modality: "A novel pegylated bispecific antibody-drug conjugate (P-BsADC) JY207b targeting cancers co-expressing PD-L1 and CD47" [DOI:10.1158/1538-7445.am2024-3126]; stage: "In CDX models and a PDX model of transplanted tumor tissues from lung cancer patients, the compound JY207b demonstrated strong tumor inhibition efficacies at low doses." [DOI:10.1158/1538-7445.am2024-3126]